Brazil is expected to get up to 150 mln doses of Russia’s Sputnik V coronavirus vaccine by the year-end after its emergency use is approved by the national pharmaceutical regulator, said Rogerio Rosso, International Business Director at Uniao Quimica pharmaceutical company, a partner of the Russian Direct Investment Fund.
"This year we will be able to provide Brazil with 150 mln doses of Sputnik V, produced in our country and in Russia," Rosso told TASS. According to Rosso, who earlier served as the governor of the federal district and a former MP, "many states in Brazil prefer Sputnik V vaccine due to its effectiveness and safety."
According to him, the company’s specialists were actively working with representatives of Brazil’s Brazilian Health Regulatory Agency (Anvisa) on registering the vaccine. "Last week we held two meetings and another one is scheduled for today," he noted.
The regulator’s permission to carry out the third phase of clinical trials of the vaccine in Brazil, which is compulsory for authorizing its emergency use, could be issued "in the coming days," and it will take another 45-60 days to conduct the study, Rosso said.
Under the agreement with RDIF, Uniao Quimica is allowed to export Sputnik V to other Latin American states, the company’s representative said. "We have launched production of an active pharmaceutical ingredient of the vaccine in a pilot scale and this is already a reason to be happy," Rosso said. He thanked RDIF and the Russian government for "the gesture of humanism for all countries."